Yunju Ma

Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations

Depei Wu, Xiaowen Tang, Jia Yin, 2021, Bone Marrow Transplantation.

Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia

A. Sun, Depei Wu, Xiaowen Tang, 2019, Bone Marrow Transplantation.

Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment.

Hong-jie Shen, Dan-dan Liu, Xiaowen Tang, 2022, American journal of cancer research.

Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation

B. Andersson, B. Valdez, Zi X. Chen, 2021, Bone Marrow Transplantation.

Case report: Rare persistent complete donor chimerism and GVHD following micro-transplantation from HLA haplotype homozygous donors

Jun He, Depei Wu, Xiaowen Tang, 2022, Frontiers in Immunology.

Familial Acute Promyelocytic Leukemia: A Case Report and Review of the Literature

Q. Cui, Yunju Ma, Xuanqi Cao, 2024, OncoTargets and therapy.

Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.

Q. Cui, Zheng Li, Xiaming Zhu, 2024, Leukemia research.